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Background and aims: Low-density lipoprotein cholesterol (LDL-C) is a key modiﬁable risk factor in the
development of cardiovascular (CV) disease. In 2012, the Japan Atherosclerosis Society (JAS) issued
guidelines recommending statins as ﬁrst-line pharmacotherapy for lowering LDL-C in patients at high
risk for CV events. This study assessed achievement of recommended LDL-C goals and lipid-modifying
therapy (LMT) use in a high CV risk population in Japan.
Methods: Patients from the Medical Data Vision (MDV) database, an electronic hospital-based claims
database in Japan, who met the following inclusion criteria were included in this study: LDL-C mea-
surement in 2013; 20 years of age; 2 years representation in the database; and a high CV risk con-
dition (recent acute coronary syndrome (ACS), other coronary heart disease (CHD), ischemic stroke,
peripheral arterial disease (PAD) or diabetes). LDL-C goal attainment was assessed based on LDL-C targets
in the JAS guidelines.
Results: A total of 33,325 high CV risk patients met the inclusion criteria. Overall, 68% of the cohort
achieved guideline recommended LDL-C targets, with only 42% receiving current treatment with statins.
Attainment of LDL-C goals was 68% for ACS, 55% for CHD, and 80% each for ischemic stroke, PAD, and
diabetes patients. Concomitant use of non-statin LMTs was low.
Conclusions: In a high CV risk population in a routine care setting in Japan, guideline recommended LDL-
C goal attainment and utilization of statins and other LMT was low. In addition, physicians appeared to be
more likely to consider the initiation of statins in patients with higher baseline LDL-C levels.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular (CV) disease is the second leading cause of
mortality in Japan, accounting for 29% of total deaths in 2012 [1].
Globally, and within Southeast Asia and Japan speciﬁcally,
abnormal lipids have been identiﬁed as having a high populationoto).
Ireland Ltd. This is an open accessattributable risk [2]. Elevated levels of low-density lipoprotein
cholesterol (LDL-C), a key modiﬁable risk factor, is associated with
an increased risk of atherosclerotic CV events including myocardial
infarction (MI), unstable angina (UA), coronary revascularization,
ischemic stroke, and CV death [3e7]. A number of large randomized
clinical trials (RCTs) with statin-based and non-statin based ther-
apies have demonstrated that a reduction in LDL-C levels results in
a reduced risk of CV events [8e11]. A meta-analysis of 26 RCTs with
statins demonstrated that each 1 mmol/L decrease in LDL-Carticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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with the relationship being consistent for populations with varying
levels of baseline risk, including primary and secondary prevention
populations, and at varying levels of baseline LDL-C [3]. Further, a
large RCT conducted in a Japanese population reported that the risk
of coronary heart disease (CHD) was 33% lower in patients treated
with statin plus diet therapy compared with patients on diet alone
[12].
Guidelines relevant to the treatment of elevated LDL-C recom-
mend treatment approaches based on patients’ CV risk proﬁle.
While major guidelines such as the American College of Cardiology/
American Heart Association (ACC/AHA), European Society of Car-
diology/European Atherosclerosis Society (ESC/EAS), National Lipid
Association (NLA), and the International Atherosclerosis Society
(IAS) differ slightly with respect to goal attainment, all recommend
statins as the ﬁrst-line drug treatment for elevated LDL-C
[4,5,13,14]. In Japan, the 2012 Japan Atherosclerosis Society (JAS)
guidelines for the diagnosis and prevention of atherosclerotic CV
diseases in Japan recommend achievement of LDL-C <100 mg/dL in
patients with established CHD and LDL-C <120 mg/dL in patients
with any of the following conditions: history of ischemic stroke,
peripheral arterial disease (PAD), diabetes mellitus (DM), and
chronic kidney disease (CKD) [6]. Among high-risk patients without
coronary artery disease (CAD), the JAS guidelines recommend
lifestyle modiﬁcation such as smoking cessation, healthy diet and
regular exercise before drug therapy is considered; however, for
those with CAD, guidelines suggest drug therapy to be simulta-
neously considered with lifestyle modiﬁcations. Similar to other
major guidelines across the world, JAS guidelines recommend
statins as ﬁrst-line pharmacotherapy for lowering LDL-C, with
consideration of non-statin lipid-modifying therapies (LMT) such
as bile acid sequestrants and/or ezetimibe either as add-on to sta-
tins or as monotherapy where statins may not be appropriate.
The objective of the current studywas to conduct a point in time
analysis to summarize LDL-C levels of patients and to examine
patients’ LDL-C goal attainment versus the recommended target
levels by the JAS guidelines using a real-world population at high
CV risk in Japan. The secondary objective was to assess the utili-
zation of statins and other LMT in this population. This study aimed
to provide insights into the utilization patterns of statins and non-
statin LMT and LDL-C goal attainment among speciﬁc sub-cate-
gories of patients considered at high risk for CV events.
2. Materials and methods
2.1. Database and cohort selection
This retrospective, cross-sectional, observational study utilized
the Medical Data Vision (MDV) database, which contains electronic
hospital-based health insurance claims and Diagnosis Procedure
Combination (DPC) data. The database represents inpatient and
outpatient medical care from a panel of 136 hospitals distributed in
different regions across Japan. All hospitals in the database were for
acute care, with an average bed number of 350. The database
contains anonymized patient-level information on demographics,
clinical diagnoses, procedures, prescriptions, and costs. Laboratory
test results are also available for a subset of patients.
Patients meeting the following inclusion criteria were selected:
at least 1 recorded LDL-C value (measured by direct assay) in 2013
with the last LDL-Cmeasurement in 2013 deﬁned as the index date,
20 years of age, and evidence for 1 of the following high CV risk
conditions: recent acute coronary syndrome (ACS; acute MI or UA
with concurrent hospitalization within 12 months prior to the in-
dex date), other CHD (any history of CHD except deﬁned as “Recent
ACS”), ischemic stroke, PAD (any history of peripheral vasculardisease, abdominal aortic aneurism, or carotid artery disease) or
DM (type 1 or type 2). All high CV-risk conditions were identiﬁed
using International Classiﬁcation of Disease, Tenth Revision (ICD-
10) codes as well as Japanese procedure codes within the MDV
database (Supplementary Table 1). All codes were carefully exam-
ined by experts to ensure selected codes represented disease states
inwhich treatmentwith statin could be realized. In order to capture
complete medical history for classiﬁcation into CV risk conditions
and to determine historical LMT use, we also required 2 years of
continuous representation in the database prior to the index date.
Patients were hierarchically classiﬁed into the highest mutually
exclusive categories in the following order: 1) recent ACS; 2) other
CHD; 3) ischemic stroke; 4) PAD; and 5) DM. For example, if an
individual had a diagnosis for both ischemic stroke and diabetes,
she/he would be categorized into the ischemic stroke category.
Patients were also examined by prevalent conditions where each
patient was placed in every disease proﬁle for which they qualiﬁed.
For example, a patient with stable CHD and symptomatic PAD was
placed in both other CHD and PAD categories.
2.2. Achieved baseline LDL-C levels
Patients’ current LDL-C level was deﬁned as the LDL-C value on
the index date. In order to ascertain goal attainment, we deﬁned
goal as <100 mg/dL for patients with recent ACS and other CHD,
and <130mg/dL for patients with ischemic stroke, PAD, or diabetes.
Although the JAS guidelines recommend an LDL-C target of
<120 mg/dL for the latter group, we retained a more conservative
threshold which is 10 mg/dL higher in order to facilitate compari-
son with studies outside Japan and maintain uniformity in LDL-C
categorization for other analyses presented in this study. We also
summarized LDL-C for all high-CV risk patients using standard LDL-
C thresholds, <70 mg/dL, 100 mg/dL, and 130 mg/dL.
Among patients on LMT, we estimated the baseline LDL-C level
which was intended to represent LDL-C levels prior to initiation of
LMT. This baseline LDL-C was estimated as current LDL-C level/
(1  expected percent LDL-C lowering by the current LMT). A
justiﬁcation of this approach is supported by the limited inﬂuence
of patient factors, including baseline LDL-C levels, on expected
percent LDL-C lowering efﬁcacy of statin and non-statin LMTs [15].
Asian patients frequently have an increased response to medica-
tions compared to patients from Western countries due to genetic
differences in drug metabolism [16]. There is very little data
available assessing the effect of statins in Asian populations, and is
mainly composed of phase II trials with small sample sizes, non-
placebo controlled studies, non-randomized studies and open-la-
bel studies [17e30]. Thus, the LDL-C lowering percentages of each
LMT were based on the data obtained from previously published
meta-analyses of large RCTs. The detailed information is presented
in Supplementary Table 2. A sensitivity analysis was also conducted
to assess the robustness of the mean LDL-C reduction used in
baseline LDL-C calculations. The co-efﬁcient of variation for LDL-C
reduction response while on treatment in randomized clinical tri-
als is approximately 36% [31,32]. Thus, the LDL-C lowering value for
each LMT utilized in the baseline LDL-C estimation calculation was
reduced by 36%.
2.3. Determination of treatment with LMT
Patients were assigned into mutually exclusive categories based
on medication status at index: 1) currently treated by LMT e if
medication supply via a recorded LMT prescription was present on
or within 30 days prior to the index date; 2) previously treated by
LMT e not currently treated but evidence of a prior recorded LMT
during the 2 year pre-index period; 3) no history of treatment with
T. Teramoto et al. / Atherosclerosis 251 (2016) 248e254250LMT e deﬁned as no recorded LMT during the 2 year pre-index
period. We further categorized LMT use into the following three
mutually exclusive categories: high-intensity statin therapy with or
without other non-statin LMT, low- to moderate-intensity statin
with or without other non-statin LMT, and non-statin LMT. High-
intensity statin included atorvastatin 20 mg, rosuvastatin
10 mg, pitavastatin 4 mg. All the other statins and doses were
classiﬁed as low- to moderate-intensity. Non-statin LMTs included
ezetimibe, niacin (nicotinic acid), and bile acid sequestrants
(cholestyramine and colestipol).
2.4. Statistical analyses
Demographic and clinical characteristics as well as LMT utili-
zation and achieved LDL-C levels were summarized descriptively
via proportions andmean ± standard deviation (SD) as appropriate.
Student’s t-test and chi-square tests were used to compare the
demographic and clinical characteristics of: 1) patients currently on
any statin therapy vs. no statin and 2) patients currently treated
with high-intensity statins vs. low- to moderate-intensity statins.
No adjustments for multiple testing were performed. All analyses
were conducted with SAS software version 9.2.
3. Results
3.1. Baseline characteristics
A total of 33,325 patients met the inclusion criteria
(Supplementary Fig. 1). The mean age (SD) was 70 (12) years and
about one ﬁfth of the sample was greater than 80 years old.
Approximately 61% weremale, 77%were hypertensive, and roughly
3% had a severely elevated LDL-C of >190 mg/dL (Table 1).
Assignment by hierarchical category resulted in the followingTable 1
Baseline characteristics for the overall population and by hierarchical categorization.
Recent ACS Other CHD
(n ¼ 1145) (n ¼ 16,045)
Age, mean (SD), years 72.7 (10.4) 72.4 (11.1)
Age >80 years, n (%) 274 (23.9) 3995 (24.9)
Male, n (%) 834 (72.8) 9948 (62.0)
Metropolitan Region, n (%) 973 (85.0) 12,066 (75.2)
BMI, mean (SD)a 23.8 (3.7) 23.9 (4.2)
Smoking index, mean (SD)a,b 476 (646) 355 (559)
eGFR (mL/min/1.73 m2), mean (SD)b 45.9 (22.7) 50.7 (22.6)
LDL-C 190 mg/dL, n (%) 37 (3.2) 385 (2.4)
HeFH, n (%)c 3 (0.3) 80 (0.5)
Recent ACS, n (%) 1145 (100.0) 0 (0.0)
Other CHD, n (%) 808 (70.6) 16,045 (100.0)
Ischemic stroke, n (%) 32 (2.8) 289 (1.8)
PAD, n (%) 289 (25.2) 2423 (15.1)
DM, n (%) 591 (51.6) 5503 (34.3)
Hypertension, n (%) 1045 (91.3) 13,751(85.7)
History of CHF, n (%) 697 (60.9) 7613 (47.4)
CKD stage III, n (%)d 547 (47.8) 7450 (46.4)
CKD stage IVeV, n (%)d 273 (23.8) 2810 (17.5)
COPD, n (%) 204 (17.8) 3225 (20.0)
Liver disease, n (%) 236 (20.6) 3252 (20.3)
Beta-blockers, n (%) 685 (59.8) 6459 (40.2)
ACEI/ARBs, n (%) 726 (63.4) 8801 (54.9)
Clopidogrel, n (%) 782 (68.3) 3096 (19.3)
ACS, acute coronary syndrome; ACEI, angiotension converting enzyme inhibitors; ARB,
failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, d
arterial disease.
a Values based on a subset (n ¼ 18,825, 56.5%) of patients with a record of inpatient d
b Smoking index ¼ (number of cigarettes per day)(number of years of smoking).
c Based on physician diagnosis.
d CKD stage III: 60 > eGFR  30; CKD stage IVeV: 30 > eGFR or hemodialysis.subgroups: 3% recent ACS (n ¼ 1145); 48% other CHD (n ¼ 16,045);
2% ischemic stroke (n ¼ 731); 9% PAD (n ¼ 3161); and 37% diabetes
(n ¼ 12,243). Categorization by prevalent conditions led to the
following proportions in these categories, respectively: 3%, 51%, 3%,
18%, and 59%.
3.2. Achievement of LDL-C levels
Overall, approximately 68% of the study cohort achieved LDL-C
goals as recommended by the JAS guidelines with a mean (SD)
LDL-C of 101.3 (30.2) mg/dL. Among the ACS and CHD populations,
56% met their LDL-C goal <100 mg/dL, although in individual
subgroups 68% and 55% of ACS and CHD patients achieved their
goals, respectively. Among those with ischemic stroke, PAD, and
diabetes, 80% (for each) met their LDL-C goal of <130 mg/dL. When
analyzing the population by LDL-C target attainment, 14%, 50%, and
84% of the population achieved <70 mg/dL, <100 mg/dL, and
<130 mg/dL, respectively.
By hierarchical risk categorization, the mean LDL-C mg/dL was
88.8 (29.9) mg/dL for recent ACS, 98.0 (29.1) mg/dL for other CHD,
105.2 (30.3) mg/dL for ischemic stroke, 104.6 (31.7) mg/dL for PAD,
and 105.7 (30.4) mg/dL for diabetes. The percentage of those
achieving an LDL-C of <100mg/dL was 68%, 55%, 44%, 45%, and 43%,
while those achieving<130mg/dLwas 92%, 87%, 80%, 80%, and 80%,
for recent ACS, other CHD, ischemic stroke, PAD, and diabetes,
respectively (Fig. 1).
3.3. Utilization of LMT
Overall, 45% of the study cohort was treated with LMT as of
index date with 42% of the study cohort receiving a statin. Treat-
ment with statins was 57%, 48%, 32%, 33%, and 35% by hierarchical
categorization of recent ACS, other CHD, ischemic stroke, PAD, andIschemic stroke PAD Diabetes Total
(n ¼ 731) (n ¼ 3161) (n ¼ 12,243) (n ¼ 33,325)
72.4 (11.8) 71.3 (11.1) 65.8 (13.1) 69.9 (12.3)
189 (25.9) 651 (20.6) 1457 (11.9) 6565 (19.7)
460 (62.9) 2058 (65.1) 6905 (56.4) 20,195 (60.6)
626 (85.6) 2753 (87.1) 10,615 (86.7) 27,027 (81.1)
22.9 (4.3) 23.0 (4.4) 24.4 (5.3) 23.9 (4.6)
286 (490) 386 (575) 292 (516) 344 (554)
55.0 (21.5) 52.9 (23.1) 58.6 (22.6) 53.7 (23.0)
23 (3.1) 111 (3.5) 575 (4.7) 1133 (3.4)
1 (0.1) 6 (0.2) 37 (0.3) 133 (0.4)
0 (0.0) 0 (0.0) 0 (0.0) 1133 (3.4)
0 (0.0) 0 (0.0) 0 (0.0) 16,862 (50.6)
731 (100.0) 0 (0.0) 0 (0.0) 1066 (3.2)
136 (18.6) 3161 (100.0) 0 (0.0) 5999 (18.0)
233 (31.9) 1113 (35.2) 12,243 (100.0) 19,662 (59.0)
582 (79.6) 2289 (72.4) 8142 (66.5) 25,794 (77.4)
192 (26.3) 692 (21.9) 1769 (14.4) 10,963 (32.9)
351 (48.0) 1351 (42.7) 4486 (36.6) 14,185 (42.6)
85 (11.6) 498 (15.8) 1399 (11.4) 5065 (15.2)
110 (15.0) 505 (16.0) 1579 (12.9) 5623 (16.9)
133 (18.2) 735 (23.3) 3600 (29.4) 7956 (23.9)
127 (17.4) 497 (15.7) 1345 (11.0) 9113 (27.3)
363 (49.7) 1419 (44.9) 5375 (43.9) 16,684 (50.1)
176 (24.1) 317 (10.0) 333 (2.7) 4704 (14.1)
angiotensin receptor blockers; CHD, coronary heart disease; CHF, congestive heart
iabetesmellitus; HeFH, heterozygous familial hypercholesterolemia; PAD, peripheral
ischarge summary.
Fig. 1. LDL-C achievement by hierarchical risk categorization. ACS, acute coronary
syndrome; CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol;
PAD, peripheral arterial disease.
T. Teramoto et al. / Atherosclerosis 251 (2016) 248e254 251diabetes, respectively. Of those treatedwith LMT, only 1% received a
high-intensity statin with this proportion being 3%, 2%, 0%, 1%, and
0% by hierarchical categorization of recent ACS, other CHD,Fig. 2. LMT utilization by hierarchical categorization. (A) Patients currently on LMT;
(B) patients with no current LMT. ACS, coronary syndrome; CHD, coronary heart dis-
ease; LMT, lipid-modifying treatment; PAD, peripheral arterial disease.ischemic stroke, PAD and diabetes, respectively (Fig. 2A). Of those
not currently treated with LMT (55% of the cohort), previous
treatment was examined and it was found that only 6% of the study
cohort had evidence of prior treatment with LMT during the 2 years
prior to the index date. This proportion was 13%, 7%, 6%, 5%, and 5%
by hierarchical categorization of recent ACS, other CHD, ischemic
stroke, PAD, and diabetes, respectively (Fig. 2B). Approximately 49%
of the study cohort did not have evidence of treatment with LMT in
the 2 years before the index date.
For patients currently treated with LMT, the use of combination
therapy was low with the majority of patients using statins as
monotherapy. Overall, 74% patients treated with high-intensity
statin were on monotherapy and 24% were concomitantly pre-
scribed ezetimibe. A majority of the patients (94%) on low- to
moderate-intensity statin were on monotherapy with only 5% also
receiving ezetimibe.
Fig. 3 shows the distribution of LMT utilization by LDL-C levels.
The utilization of LMTwas higher in the patients achieving LDL-C of
<100 mg/dL compared to those with LDL-C 100 mg/dL. For
example, 52% of the patients were receiving LMT who achieved
LDL-C of <70 mg/dL compared to only 35% of those with LDL-C
160 mg/dL.
An unadjusted comparison indicated that patients on statin
treatment (as compared with no statin treatment) weremore likely
to be female, have a severely elevated LDL-C level of 190 mg/dL,
coronary high-risk conditions (recent ACS and other CHD), hyper-
tension, and congestive heart failure (CHF). Patients treated with
statins were also more likely to be receiving treatment with other
CV medications. Patients treated with high-intensity statins (as
compared with low- to moderate-intensity statins) were more
likely to be younger, male, have severely elevated LDL-C levels of
190 mg/dL, coronary high-risk conditions (recent ACS and other
CHD), hypertension, CHF, and no concomitant diabetes. Patients
treated with high-intensity statins were also more likely to be
receiving treatment with other CV medications (Supplementary
Table 3).
3.4. LMT utilization by estimated baseline LDL-C
The utilization of LMT was further examined against the esti-
mated baseline LDL-C levels, deﬁned as expected LDL-C level inFig. 3. LMT utilization by LDL-C levels. LDL-C, low-density lipoprotein cholesterol;
LMT, lipid-modifying treatment.
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methods). Within each hierarchical risk subgroup, patients with
higher baseline LDL-C were more likely to be treated with LMT,
especially with a statin. Within all subgroups, the proportion of
patients on statin therapy increased progressively with increasing
baseline LDL-C levels. In the recent ACS group, only 25% of the
patients with baseline LDL-C <70 mg/dL were treated with a statin.
However, in patients whose baseline LDL-C was 160 mg/dL, 74%
were treated with a statin (Fig. 4A). The same patternwas observed
in the hierarchical subgroups representing other CHD, ischemic
stroke, PAD, and diabetes (Fig. 4BeE). The likelihood of receiving
statin therapy also increased progressively according to the pre-
sumed severity of CV risk. For example, within each baseline LDL-C
category, the proportion of patients receiving statin therapy was
consistently higher in those with recent ACS and other CHD as
compared to those with ischemic stroke, PAD, or diabetes (Fig. 4). In
the sensitivity analysis, the same trend, that those with higher
baseline LDL-C levels were more likely to be treated with LMT, was
seen (results not shown).Fig. 4. LMT types by estimated baseline LDL-C levels. (A) Recent ACS, (B) other CHD, (C) isc
heart disease; LDL-C, low-density lipoprotein cholesterol; LMT, lipid-modifying treatment;4. Discussion
In this study, we assessed the LDL-C attainment and LMT utili-
zation patterns in a high CV risk population in Japan and examined
the ﬁndings against recommendations from the JAS 2012 guide-
lines, although we utilized a more conservative approach by using
an LDL-C value of 130 mg/dL in lieu of 120 mg/dL. Only 56% of the
high-risk subgroups with recent ACS and other CHD met the JAS
guidelines LDL-C goal of <100 mg/dL, where the recommendation
is to consider LMT together with lifestyle modiﬁcation. When the
less aggressive LDL-C goals were examined for the subgroups with
ischemic stroke, PAD, and diabetes, 80% met the JAS guidelines of
achieving and LDL-C <130 mg/dL where the recommendation is to
consider LMT after lifestyle modiﬁcation.
The ﬁndings from our study are consistent with previous studies
examining LDL-C achievement in high-risk populations in Japan as
well as other Asian countries. A multicenter, retrospective study of
Japanese adults taking dyslipidemia medications in 2009 reported
that 45% of CAD patients (population with recent ACS or CHD)hemic stroke, (D) PAD, and (E) diabetes. ACS, acute coronary syndrome; CHD, coronary
PAD, peripheral arterial disease.
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or diabetes achieved LDL-C <120 mg/dL [33]. Another cross-
sectional survey on patients with dyslipidemia on statin therapy
in Japan reported that 25% of CAD patients in achieved an LDL-C of
<100 mg/dL while 57% of high-risk non-CAD achieved LDL-C of
<120 mg/dL [34]. Moreover, similar LDL-C attainment trends were
reported in other Asian countries. A Pan-Asian cross-sectional
survey was conducted in eight Asian countries for hypercholes-
terolemia patients treated with lipid-lowering pharmacological
treatment [35]. Overall LDL-C goal attainment was reported in
49.1% of patients, with speciﬁc LDL-C goal attainment in 34.9%,
55.3%, and 75.4% of patients with very high-risk (LDL-C goal of
<70 mg/dL), high risk (LDL-C goal of >100 mg/dL), and moderate
risk (LDL-C goal of <130 mg/dL) of CV events, respectively. Our
study indicated a somewhat higher LDL-C goal attainmentwith 56%
of the CAD patients achieving LDL-C of <100mg/dL. The variation in
ﬁndings can be due to differences in study population and design of
previous studies, which speciﬁed elevated LDL-C or treatment with
LMT as part of inclusion criterion. For patients currently on LMT in
our study, 58% achieved an LDL-C level less than 100 mg/dL, which
was consistent with the previous studies for subjects on LMT.
Despite these differences, our conclusions were consistent in that
the LDL-C targets set by JAS were not fully achieved.
Our study also found that only 45% of the study population
was currently receiving treatment with any LMT, with 42% of the
study population receiving treatment with statins. In addition,
high-intensity statins were found to be underutilized. Although
the study population was not fully comparable, these proportions
are similar to, but slightly lower than those from the Interna-
tional Reduction of Atherothrombosis for Continued Health
(REACH) study where 51% of the high-risk patients were on LMT
and 45% were on statins [36]. The slight discrepancy is poten-
tially due to the different inclusion criteria in the REACH study
with a requirement for at least 45 years of age with established
CAD, cerebrovascular disease, or PAD, or with at least three
atherosclerosis risk factors. Statin underutilization has also been
reported in studies based in other countries. A study based on
data from the 2010 Medial Expenditure Panel Survey in the US
reported that only 58% of patients with CHD and 52% of patients
with diabetes were treated with a statin [37]. One possible
reason for low LMT use in Japan is that guidelines recommend
that the lipid management goals should generally be achieved
via lifestyle modiﬁcation for all patients, with drug therapies to
“be considered” even for patients with a history of CHD [6].
Another possible reason for somewhat lower rates of LMT and
statin use in our deﬁnition of “current treatment,” with patients
being considered to be treated only if medication supply via
recorded prescription was present on or within 30 days prior to
the index date. The total proportion of patients who received
prior (in the last 2 years) or current LMT was 51% and 47%,
respectively.
Our investigation of the utilization patterns of statins by pa-
tients’ baseline LDL-C levels suggests that in Japan the likelihood of
patients receiving treatment by statins increases with increasing
baseline LDL-C levels. Thus, even among the subgroup with base-
line LDL-C levels exceeding guideline recommendations (e.g. a CHD
subgroup with baseline LDL-C >100 mg/dL), those with baseline
LDL-C levels farther from the recommended threshold (e.g. those
with LDL-C from 130 to 160mg/dL or >160mg/dL) weremore likely
to receive statin therapy. Although JAS guidelines do not require
consideration of the initiation of a statin based on distance from
LDL-C goal, our data suggest that in real-world practice physicians
are likely to consider distance from goal in treatment decisions.
Taking into account that pharmacotherapy is only a consideration,
it is possible that physicians would manage with lifestylemodiﬁcation only for patients within a reasonable distance from
their LDL-C goal.
In terms of the effectiveness of statins in facilitating LDL-C goal
achievement, it is difﬁcult to derive robust conclusions from the
study in light of its observational nature. However, more patients
who achieved LDL-C <100 mg/dL were treated with statins, as
compared to those with LDL-C100mg/dL, which suggests the key
role of statins in facilitating LDL-C goal achievement and ultimately
reductions in CV risk.
Our study has several notable limitations. Ischemic stroke
represented a relatively small proportion of patients in our study.
A possible explanation is the requirement of a LDL-C measure-
ment, which may result in an underestimation of this population
if LDL-C is not measured frequently in ischemic stroke patients in
Japan. Thirdly, rural populations were underrepresented, which
may further limit the generalizability of ﬁndings. However, the
database included hospitals with outpatient and inpatient ser-
vices, which reﬂected the system in Japan. In addition, 55% of the
patients in the current study visited outpatient clinics only, indi-
cating good coverage of both inpatients and outpatients. Although
there may be differences between inpatient and outpatients due
to acute cases of hospitalization potentially affecting LDL-C levels,
our primary focus was on their prior treatments and their current
LDL-C level utilizing the prior 2 years. Regarding LDL-C mea-
surement, the data were obtained from the record of direct assay
and were limited for patients with multiple assays only. Addi-
tionally, due to the lack of robust data demonstrating a differential
LDL-C lowering of statins in a Japanese population, the baseline
LDL-C was estimated using data from large meta-analyses of
clinical trials whichmay not reﬂect real-world treatment effects. If
Japanese patients have a heightened response to statins compared
with Western patients, the baseline LDL-C estimates may be
underestimated. Furthermore, LDL-C data was derived from hos-
pitals, where LDL-C is measured after adequate fasting; however,
the current dataset does not guarantee that all patients conducted
adequate fasting prior to lab tests. Lastly, the database cannot
capture potential health services, including prescriptions, that
were obtained at institutions outside of the panel represented in
the database. We explored whether this limitation might be
relevant and if it could impact the estimates of measures such as
LMT or statin utilization by examining the overall distributions of
prescription-related encounters in the study cohort during past 3
years for any medication, and concluded that most patients
received prescriptions within the institutions represented in the
database.
The present study concluded that in a high-risk cohort in Japan
only 68% achieved guideline-recommended LDL-C goals and only
42% were treated with a statin, suggesting that statins are
underutilized in Japanese high-risk populations. This represents an
opportunity to increase statin utilization in order to further
decrease residual risk.Conﬂict of interest
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